According to the new research report published by Precedence Research, titled “Non-opioid Pain Treatment Market (By End User: NSAIDs, Acetaminophen, Local Anesthetics, Others; By Administration Analysis: Chronic Pain, Post-operative Pain, Cancer Pain, Others; By Route of Administration: Oral, Topical, Injectable, Others; By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Others) – Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032 (By Product: Traditional, Advanced; By Application: Pottery, Tiles, Abrasives, Sanitary wave, Bricks & pipes, Others; By End User: Medical, Industrial, Building & Construction, Others) – Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032”, the global non-opioid pain treatment market size is expected to be worth around US$ 79.7 billion by 2032 and is poised to record a yearly growth rate of 6.54% from 2023 to 2032. The study investigates several elements and their consequences on the growth of the all-wheel drive market.
This report focuses on non-opioid pain treatment market volume and value at the global level, regional level and company level. From a global perspective, this report represents the overall non-opioid pain treatment market size by analysing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, the Middle East & Africa, Latin America, etc.
The research report includes specific segments by region (country), by company, by all segments. This study provides information about the growth and revenue during the historic and forecasted period of 2017 to 2032. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Download a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/2612
The study also provides important advancements in organic and inorganic growth strategies in the worldwide non-opioid pain treatment market. A lot of corporations are prioritizing new launches, product approvals, and other business expansion techniques. In addition, the report offers profiles of non-opioid pain treatment market firms and market strategies. Furthermore, the research focuses on top industry participants, providing information such as company profiles, components and services offered, recent financial data, and key developments.
Non-opioid Pain Treatment Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 45.07 Billion |
| Market Size by 2032 | USD 79.7 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 6.54% |
| Largest Market | North America |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Drug Class, By Pain Type, By Route of Administration and By Distribution Channel |
Also read: Submarine Cable System Market Size to Worth US$ 41.02 Billion By 2032
Market Key Players
Company profiles have been included in the report, which include essentials such as product portfolio, key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting market status and predicting the competition level in the non-opioid pain treatment market.
Some of the prominent players in the non-opioid pain treatment market include
- Novartis AG
- Teva Pharmaceutical Industries Limited
- Dr. Reddy’s Laboratories Ltd
- Sun Pharmaceutical Industries Ltd
- GSK plc.
- Pfizer Inc.
- Perrigo Company plc,
- LNK International, Inc.
- Cipla Inc.
- Johnson & Johnson Services, Inc.
- Pacira Pharmaceuticals, Inc.
- Pierrel
Non-opioid Pain Treatment Market Segmentations
By Drug Class
- NSAIDs
- Selective COX-2 Inhibitors
- Non-Selective NSAIDs
- Acetaminophen
- Local Anesthetics
- Others
By Pain Type
- Chronic Pain
- Neuropathic Pain
- Inflammatory Conditions
- Post-operative Pain
- Cancer Pain
- Others
By Route of Administration
- Oral
- Topical
- Injectable
- Others
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Others
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- The Middle East and Africa
Report Objectives
- To define, segment, and project the global market size for non-opioid pain treatment market
- To understand the structure of the market by identifying its various sub-segments
- To provide detailed information about the key factors influencing the growth of the market (drivers, restraints, opportunities, and industry-specific challenges)
- To analyse the micro-markets, with respect to individual growth trends, future prospects, and their contributions to the total market
- To project the size of the market and its submarkets, in terms of value, with respect to global. (along with their respective key countries)
- To profile key players and comprehensively analyse their core competencies
- To understand the competitive landscape and identify major growth strategies adopted by players across the globe.
- To analyse the competitive developments such as expansions & investments, new product launches, mergers & acquisitions, joint ventures, and agreements
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Non-opioid Pain Treatment Market
5.1. COVID-19 Landscape: Non-opioid Pain Treatment Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Non-opioid Pain Treatment Market, By Drug Class
8.1. Non-opioid Pain Treatment Market, by Drug Class, 2023-2032
8.1.1. NSAIDs
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Acetaminophen
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Local Anesthetics
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Others
8.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Non-opioid Pain Treatment Market, By Pain Type
9.1. Non-opioid Pain Treatment Market, by Pain Type, 2023-2032
9.1.1. Chronic Pain
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Post-operative Pain
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Cancer Pain
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Non-opioid Pain Treatment Market, By Route of Administration
10.1. Non-opioid Pain Treatment Market, by Route of Administration, 2023-2032
10.1.1. Oral
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Topical
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Injectable
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Non-opioid Pain Treatment Market, By Distribution Channel
11.1. Non-opioid Pain Treatment Market, by Distribution Channel, 2023-2032
11.1.1. Hospital Pharmacy
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Retail Pharmacy
11.1.2.1. Market Revenue and Forecast (2020-2032)
11.1.3. Others
11.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global Non-opioid Pain Treatment Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.1.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.1.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.1.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.1.5.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.1.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.1.6.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.1.6.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.2.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.2.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.2.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.2.5.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.2.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.2.6.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.2.6.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.2.7.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.2.7.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.2.8.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.2.8.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.3.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.3.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.3.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.3.5.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.3.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.3.6.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.3.6.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.3.7.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.3.7.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.3.8.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.3.8.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.4.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.4.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.4.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.4.5.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.4.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.4.6.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.4.6.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.4.7.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.4.7.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.4.8.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.4.8.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.5.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.5.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.5.5.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.5.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.5.6.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.5.6.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
Chapter 13. Company Profiles
13.1. Novartis AG
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Teva Pharmaceutical Industries Limited
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Dr. Reddy’s Laboratories Ltd
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Sun Pharmaceutical Industries Ltd
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. GSK plc.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Pfizer Inc.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Perrigo Company plc,
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. LNK International, Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Cipla Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Johnson & Johnson Services, Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Why should you invest in this report?
If you are aiming to enter the global non-opioid pain treatment market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for non-opioid pain treatment are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2023-2030 so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
